Get informed when a big investor buys or sells
+ Follow281.43%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bonus BioGroup (BONS.TA) currently reports a ROE of 281.43%. That is above the Healthcare sector average of 13.1%. Use the charts on this page to explore Bonus BioGroup's ROE history and peer comparisons.
Bonus BioGroup's ROE of 281.43% is higher than the Healthcare sector average of 13.1%. That is roughly 2047.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Bonus BioGroup's current 281.43% should be judged against Healthcare norms (sector average: 13.1%) and against BONS.TA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 281.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Bonus BioGroup, and consider following BONS.TA for alerts when major investors trade the stock.
Bonus BioGroup is classified in the Healthcare sector. On ROE, it currently shows 281.43% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BONS.TA with unrelated industries.